Quarterly report pursuant to Section 13 or 15(d)

Agreements with Incyte Corporation - Collaboration Agreement (Details)

v3.10.0.1
Agreements with Incyte Corporation - Collaboration Agreement (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 08, 2018
Sep. 30, 2018
Sep. 30, 2018
Dec. 31, 2017
Agreements with Incyte Corporation        
Revenue recognized   $ 400 $ 1,200  
Deferred revenue        
Deferred revenue   11,095 11,095 $ 0
Deferred revenue, current   7,075 7,075  
Deferred revenue, long-term   4,020 4,020  
Incyte | Collaboration Agreement        
Agreements with Incyte Corporation        
Up-front consideration $ 10,000      
Up-front consideration, cash 2,500      
Up-front consideration, pre-paid research funding 7,500      
Maximum target selection milestone payments and option exercise fees the Company is eligible to receive 54,000      
Maximum development and regulatory milestone payments the Company is eligible to receive for each of the validated targets 50,000      
Maximum commercial milestone payments the Company is eligible to receive for each of the validated targets if products arising from collaboration are approved $ 65,000      
Period of written notice to terminate the agreement by Incyte 60 days      
Period of written notice to terminate the agreement by the Company in the event the counterparty or one of its affiliates or sublicenses challenges the validity or enforceability of certain patent rights controlled by the Company 30 days      
Period of written notice to terminate the agreement by either of the parties in the event of an uncured material breach of the collaboration agreement by the other party 30 days      
Total transaction price $ 12,300      
Upfront non-refundable and non-creditable payment 2,500      
Prepaid research amount 7,500      
Premium paid on equity investment $ 2,300      
Deferred revenue        
Deferred revenue   11,100 11,100  
Deferred revenue, current   7,100 7,100  
Deferred revenue, long-term   $ 4,000 $ 4,000